Prescient Therapeutics Limited (ASX: PTX)
Health Care · Biotechnology · AU
AU$0.06
-12.12% today · +38.1% 1Y
Prescient Therapeutics Limited (ASX: PTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.16M and employs 3 people.
Over the last twelve months the share price has gained 38.1%, trading between 0.04 and 0.13.
Tweenvest scores Prescient Therapeutics Limited across four factors: quality 39/100, value 54/100. Its strongest factor is value.
PTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.16M
- Revenue (TTM)
- $2.39M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- AU$0.13
- 52-week low
- AU$0.04
- Avg volume (3M)
- —
- Shares outstanding
- 1.14B
- Employees
- 3
- Next earnings
- —
About Prescient Therapeutics Limited
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
- ISIN
- AU000000PTX3
- Founded
- 1986
- Listed since
- Jan 3, 1999
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cytogen, Inc.KOSDAQ: A217330 | $46.75M | ₩2,695.00 | -7.86% |
| Solasia Pharma K.K.TSE: 4597 | $46.69M | ¥27.00 | -6.90% |
| OncoTherapy Science, Inc.TSE: 4564 | $46.54M | ¥18.00 | -5.26% |
| Apollomics, Inc.NasdaqCM: APLM | $46.34M | $21.10 | -1.86% |
| ImageneBio, Inc.NasdaqCM: IMA | $45.86M | $4.04 | -4.72% |
| Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN | $45.23M | $2.23 | -3.04% |
| Mereo BioPharma Group plcNasdaqCM: MREO | $44.98M | $0.28 | -1.98% |
| GenMont Biotech IncorporationTWSE: 3164 | $44.54M | NT$16.80 | -0.88% |
Figures last refreshed Oct 18, 2026.